Florida legislation · 2026 Regular Session
Florida S844: Sickle Cell Disease Care Management and Treatment Continuing Education
Status: Chaptered, March 30, 2026
Revising requirements for a continuing education course on prescribing controlled substances which health care practitioners are required to complete, etc.
What the bill says
An act relating to sickle cell disease care management and treatment continuing education; amending s. 456.0301, F.S.; revising requirements for a continuing education course on prescribing controlled substances which health care practitioners are required to complete; providing an effective date.
From the enrolled text, March 18, 2026:
An act relating to sickle cell disease care management and treatment continuing education; amending s. 456.0301, F.S.; revising requirements for a continuing education course on prescribing controlled substances which health care practitioners are required to complete; providing an effective date. Be It Enacted by the Legislature of the State of Florida: Section 1. Paragraph (a) of subsection (1) of section 456.0301, Florida Statutes, is amended to read: 456.0301 Requirement for instruction on controlled substance prescribing.-- (1)(a) The appropriate board shall require each person registered with the United States Drug Enforcement Administration and authorized to prescribe controlled substances pursuant to 21 U.S.C. s. 822 to complete a board-approved 2-hour continuing education course on prescribing controlled substances offered by a statewide professional association of physicians in this state that is accredited to provide educational activities designated for the American Medical Association Physician's Recognition Award Category 1 Credit or the American Osteopathic Category 1-A continuing medical education credit as part of biennial license renewal. The course must include information on the current standards for prescribing controlled substances, particularly opiates; alternatives to these standards; nonpharmacological therapies; prescribing emergency opioid antagonists; [DELETED: and] the risks of opioid addiction following all stages of treatment in the management of acute pain; and the treatment of pain for patients with sickle cell disease. The course may be offered …
Sponsors
- Jones, Shev (D, SD-034) · primary sponsor
Latest actions
- : Chapter No. 2026-6
- : Approved by Governor
- : Signed by Officers and presented to Governor
- : Ordered enrolled
- : CS passed; YEAS 113, NAYS 0
- : Read 3rd time
- : Added to Third Reading Calendar
- : Read 2nd time
- : Bill added to Special Order Calendar (3/11/2026)
- : Added to Second Reading Calendar
Votes
- House: S 844 c1 (March 11, 2026): 113 yea, 0 nay, passed
- Senate: S 844 c1 (February 25, 2026): 37 yea, 0 nay, passed
- Senate: S 844 c1 (February 18, 2026): 19 yea, 0 nay, passed
- Senate: S 844 Filed (February 12, 2026): 9 yea, 0 nay, passed
- Senate: S 844 Filed (February 2, 2026): 11 yea, 0 nay, passed
Subjects: Community Affairs, Appropriations Committee on Health and Human Services, Fiscal Policy, Rules, Health Policy, Judiciary
Common questions
- What is S844?
- S844 is a bill in the Florida Legislature (2026 Regular Session): Sickle Cell Disease Care Management and Treatment Continuing Education.
- What does S844 do?
- In its own words: An act relating to sickle cell disease care management and treatment continuing education; amending s. 456.0301, F.S.; revising requirements for a continuing education course on prescribing controlled substances which health care practitioners are required to complete; providing an effective date.
- What is the status of S844?
- Chaptered as of March 30, 2026. Latest action: Chapter No. 2026-6 (March 30, 2026).
- Who sponsored S844?
- Jones, Shev (D, SD-034).
- Where is the official record for S844?
- On the Florida Legislature website: https://www.flsenate.gov/Session/Bill/2026/844
Source: official Florida record. Tracked by Delilah, AI for legislation across all 50 states and Congress.